Northwest Biotherapeutics (NWBO) Cash from Investing Activities Growth (1y) (2011 - 2026)
Northwest Biotherapeutics (NWBO) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 62.68% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -674.01% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -166.24% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Northwest Biotherapeutics | 272.75 Mn | 270.97 Mn | - | -38.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.71% |
| Dec 31, 2025 | -1,060.26% |
| Sep 30, 2025 | -191.48% |
| Jun 30, 2025 | 41.65% |
| Mar 31, 2025 | 61.09% |
| Dec 31, 2024 | 81.34% |
| Sep 30, 2024 | 59.73% |
| Jun 30, 2024 | 58.29% |
| Mar 31, 2024 | 82.07% |
| Dec 31, 2023 | 80.65% |
| Sep 30, 2023 | -58.33% |
| Jun 30, 2023 | -206.13% |
| Mar 31, 2023 | -2,198.28% |
| Dec 31, 2022 | -39.09% |
| Sep 30, 2022 | 89.74% |
| Jun 30, 2022 | 72.93% |
| Mar 31, 2022 | 78.03% |
| Dec 31, 2021 | 48.81% |
| Sep 30, 2021 | 29.22% |
| Jun 30, 2021 | -21.14% |